International audienceIn this issue of Cancer Cell, Dahan and colleagues demonstrate that modified Fc regions of agonistic anti-human CD40 mAbs can drastically increase their efficiency in a mouse pre-clinical model expressing human CD40 and IgG receptors. This study also highlights the fine balance between increased treatment efficacy and secondary side effects
This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours inclu...
Background: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and i...
International audienceIn this issue of Cancer Cell, Dahan and colleagues demonstrate that modified F...
Immunomodulatory mAbs, led by the anti-CTLA4 mAb ipilimumab, are an exciting new class of drugs capa...
sults with ‘‘checkpoint blocker’ ’ mAbs designed to antagonize related protein (GITR), in clinical d...
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as the...
Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging t...
Fc gamma receptors (FcγRs) are the major family of receptors responsible for interacting with immuno...
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction ...
BACKGROUND: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
SummaryTherapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by eng...
In recent years, monoclonal antibodies (mAbs) have established themselves as the most rapidly expand...
Specific monoclonal antibodies (mAb) against CD40 and CD137 were used to deliver a signal through th...
Isotype plays a crucial role in therapeutic monoclonal antibody (mAb) function, mediated in large pa...
This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours inclu...
Background: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and i...
International audienceIn this issue of Cancer Cell, Dahan and colleagues demonstrate that modified F...
Immunomodulatory mAbs, led by the anti-CTLA4 mAb ipilimumab, are an exciting new class of drugs capa...
sults with ‘‘checkpoint blocker’ ’ mAbs designed to antagonize related protein (GITR), in clinical d...
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as the...
Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging t...
Fc gamma receptors (FcγRs) are the major family of receptors responsible for interacting with immuno...
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction ...
BACKGROUND: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
SummaryTherapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by eng...
In recent years, monoclonal antibodies (mAbs) have established themselves as the most rapidly expand...
Specific monoclonal antibodies (mAb) against CD40 and CD137 were used to deliver a signal through th...
Isotype plays a crucial role in therapeutic monoclonal antibody (mAb) function, mediated in large pa...
This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours inclu...
Background: Stimulation of CD40 can augment anti-cancer T cell immune responses by triggering effect...
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and i...